Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CYCLERION THERAPEUTICS, INC.

(CYCN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
3.08(c) 2.94(c) 2.94(c) 3.1(c) 3.12(c) Last
289 858 361 095 334 795 700 972 925 977 Volume
-5.81% -4.55% 0.00% +5.44% +0.65% Change
More quotes
Estimated financial data (e) (USD)
Sales 2019 4,51 M - -
Net income 2019 -123 M - -
Net cash position 2019 21,0 M - -
P/E ratio 2019 -0,61x
Yield 2019 -
Sales 2020 2,30 M - -
Net income 2020 -77,8 M - -
Net cash position 2020 8,66 M - -
P/E ratio 2020 -1,20x
Yield 2020 -
Capitalization 135 M 135 M -
EV / Sales 2019 11,9x
EV / Sales 2020 41,5x
Nbr of Employees 34
Free-Float 86,3%
More Financials
Company
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to develop treatments for serious central nervous system (CNS) diseases through the discovery, development and commercialization of medicines. Its lead product, CY6463 (previously known as IW-6463), is a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator is in clinical development for Mitochondrial... 
Sector
Biotechnology & Medical Research
Calendar
09/30 | 02:40pmPresentation
More about the company
All news about CYCLERION THERAPEUTICS, INC.
09/08CYCLERION THERAPEUTICS : to Participate in Two Upcoming Investor Conferences
AQ
08/24CYCLERION THERAPEUTICS : to Present at Annual Biomarkers for Alzheimer's Disease..
AQ
08/23CYCLERION THERAPEUTICS : to Present at Annual Biomarkers for Alzheimer's Disease..
AQ
08/19CYCLERION THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8..
AQ
08/19Cyclerion Therapeutics, Inc. Announces Resignation of Kevin B. Churchwell fro..
CI
07/29CYCLERION THERAPEUTICS : Continuing to progress clinical development of CY6463, ..
PU
07/29CYCLERION THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
AQ
07/29Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corp..
GL
07/29Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter ..
CI
07/29CYCLERION THERAPEUTICS, INC. : Results of Operations and Financial Condition, Fi..
AQ
07/29Cyclerion Therapeutics, Inc Announces Earnings Results for the Second Quarter..
CI
07/23CYCLERION THERAPEUTICS : to Present Clinical Trial Design for CY6463 Phase 2a St..
AQ
07/22Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a S..
GL
07/22Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a S..
CI
07/09CYCLERION THERAPEUTICS : Expands Collaboration With Beacon Biosignals to Guide '..
MT
More news
News in other languages on CYCLERION THERAPEUTICS, INC.

- No features available -

More news
Chart CYCLERION THERAPEUTICS, INC.
Duration : Period :
Cyclerion Therapeutics, Inc. Technical Analysis Chart | CYCN | US23255M1053 | MarketScreener
Technical analysis trends CYCLERION THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
Peter M. Hecht Chief Executive Officer & Director
Anjeza Gjino Chief Financial Officer & Secretary
Marsha H. Fanucci Chairman
Andreas Eugen Busch Chief Scientific Officer
Cheryl Gault Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
CYCLERION THERAPEUTICS, INC.1.96%135
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420